1. Transforming Real-World Data into Structured, Usable Intelligence: Using our enterprise-level RWD ecosystem, Zephyr built PRISM—an AI-enabled clinical inference engine that converts messy, multi-modal patient data into structured, inference-ready patient journeys. PRISM unlocks the full potential of RWD for scalable clinical insights, machine learning development, and validation.
2. Multi-Modal AI for Predictive Modeling and Expression Reconstruction: Zephyr’s AI models predict drug response and reconstruct gene expression from clinically available inputs such as NGS data from commercial LDTs and whole-slide images (WSI). These capabilities enable retrospective validation of treatment predictions across oncology, linking molecular and clinical outcomes in real-world settings.
3. Partner-Ready Software for Rapid Co-Development and Clinical Integration: Zephyr’s foundation models can be fine-tuned for new assets, diagnostics, or therapeutic areas using partner data—delivering bespoke, AI solutions that integrate as software directly into existing R&D and clinical workflows. Our infrastructure also supports rapid clinical intelligence queries and cohorting, empowering data-driven decision-making from discovery through commercialization.